Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of IdeS for Desensitization in Kidney Transplant Candidates with Positive Crossmatch
2016-002064-13Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Jul 2016
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in chronic kidney disease (CKD) and Allosensitization, sponsored by Hansa Biopharma. Primary endpoint: Primary endpoint: crossmatch conversion. Started Jul 2016; status: completed.
02
Drugs
imlifidase
03
Conditions
chronic kidney disease (CKD)Allosensitization
Beyond the preview
Go deeper on 2016-002064-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002064-13.